OMIC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.55% compare to its pairs and should correct upwards.

Stats
Šios dienos apimtis	18 861
Vidutinė apimtis	5 536
Rinkos kapitalizacija	20.87M
EPS	$-0.340 ( Q1 \| 2024-05-14 )
Kita pelno data	( $-8.88 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.220 (Sector) 42.63 (Industry) 78.56
ATR14	$0.222 (2.61%)

GCTK 0.50%

GMVDW -1.13%

LUCY 50.00%

LUCYW 2.97%

NXGLW 0.00%

NYXH -0.57%

OMIC -9.33%

POCI 0.51%

Insider Trading

Date	Person	Action	Amount	type
2024-06-15	Meeter Dalen	Buy	6 250	Common Stock
2024-06-15	Meeter Dalen	Sell	6 250	Restricted Stock Units
2024-06-15	Glezer Eli N.	Buy	7 500	Common Stock
2024-06-15	Glezer Eli N.	Sell	7 500	Restricted Stock Units
2024-06-15	Spaventa Andrew	Buy	14 584	Common Stock

INSIDER POWER
44.10
Last 98 transactions
Buy: 5 152 178 \| Sell: 2 090 858

Koreliacija (AI algo v.1.1b): Undervalued: 0.55% $8.55 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.04 (neutral)

Trumpas: -0.54 (weak negative)

Signal:(36.887) Neutral

Singular Genomics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Singular Genomics Koreliacija - Valiuta/Žaliavos

-0.16
( neutral )

-0.39
( neutral )

0.04
( neutral )

-0.11
( neutral )

-0.39
( neutral )

0.53
( weak )

Singular Genomics Finansinės ataskaitos

Annual	2023
Pajamos:	$2.91M
Bruto pelnas:	$-558 000 (-19.17 %)
EPS:	$-1.300

FY	2023
Pajamos:	$2.91M
Bruto pelnas:	$-558 000 (-19.17 %)
EPS:	$-1.300

FY	2022
Pajamos:	$765 000
Bruto pelnas:	$-24 000.00 (-3.14 %)
EPS:	$-1.240

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.377

Financial Reports:

No articles found.

Singular Genomics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Singular Genomics

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.